Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

2019235 citationsJournal Articlebronze Open Access

Authors

Ugo De Giorgi · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori

Giuseppe Procopio · Fondazione IRCCS Istituto Nazionale dei Tumori

Diana Giannarelli · National Cancer Institute

Roberto Sabbatini · University of Modena and Reggio Emilia

Alessandra Bearz · Centro di Riferimento Oncologico

Sebastiano Buti · University of Parma

Umberto Basso

Abstract

Normal BMI combined with inflammation tripled the risk of death, suggesting that these biomarkers are critical prognostic factors for OS in patients with RCC treated with nivolumab.

Topics & Keywords

Inflammatory Biomarkers in Disease Prognosis Cancer Immunotherapy and Biomarkers Multiple and Secondary Primary Cancers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 13, pp. 3839-3846

DOI: 10.1158/1078-0432.ccr-18-3661

Field-Weighted Citation Impact: 15.34